Finance and funding: latest news

Finance and funding features

Finance and funding news from aidsmap

More news

Finance and funding news selected from other sources

  • HCV Drugs Costly but Cure Might Not Be

    Despite controversy over the cost of new hepatitis C (HCV) medications, they appear to be cheaper on a per-cure basis than earlier drugs, a researcher said here.

    04 March 2015 | MedPage Today
  • Payment delays dent India's flagship health, AIDS programs

    India's main public health programs, aimed at millions of rural poor, have been in disarray for months because the government changed the way that over $1.3 billion in federal funds were distributed, according to data and letters seen by Reuters.

    03 March 2015 | Reuters
  • London HIV Prevention Contract awarded to GMI Partnership & NHS Freedoms Shop

    The leading London HIV Prevention provider GMI Partnership led by METRO Charity with Positive East and West London Gay Men's Project and working with NHS Freedoms Shop has been awarded just under £1 million over two years to continue to provide outreach and condom distribution across London to gay and bisexual men and other men who have sex with men (MSM).

    03 March 2015 | Metro Centre press release
  • Gilead avoids billions in U.S. taxes on its $1,000-a-pill drug

    Gilead Sciences Inc., whose $1,000-a-pill hepatitis C treatment is one of the world's most expensive drugs, is avoiding billions of dollars in U.S. taxes by booking profits overseas.

    27 February 2015 | Chicago Tribune
  • HIV Prevention Cuts Medical Costs

    Averting a single infection could save up to $338,000 over a lifetime.

    27 February 2015 | MedPage Today HIV/AIDS
  • amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

    The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

    19 February 2015 | amfAR
  • The Drug That Is Bankrupting America

    With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

    18 February 2015 | Huffington Post
  • The final push for HIV in new global development agenda

    Marielle Hart, policy manager for the International HIV/AIDS Alliance and STOP AIDS NOW! is campaigning hard to ensure HIV is not buried under the mountain of competing priorities when a new global development agenda is finalised by the UN this September.

    13 February 2015 | Key Correspondents
  • Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

    Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

    13 February 2015 | Reuters
  • Gilead faces challenge to European patent on pricey hep C drug

    Global health charity Medecins du Monde (MdM) launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of charging "exorbitant" prices for a hepatitis C drug.

    10 February 2015 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.